Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 8/20 | 0.47 |
| ▸ | BRD9 | Q9H8M2 | 4/20 | 0.47 |
| ▸ | BPTF | Q12830 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL979278 | 0.78 | KAT2B (0.60) | KAT2BBRD9BPTFALDH1A1HPGD | |
| SCHEMBL2642056 | 0.77 | KAT2B (0.53) | KAT2BBRD9BPTFALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL17912386 | 0.77 | KAT2B (0.58) | KAT2BBRD9BPTFALDH1A1HPGD | |
| SCHEMBL8544499 | 0.77 | BRD9 (0.48) | KAT2BBRD9BPTFALDH1A1HPGD | |
| SCHEMBL17912381 | 0.75 | KAT2B (0.47) | KAT2BBRD9BPTFALDH1A1HPGD | |
| SCHEMBL15282281 | 0.75 | KAT2B (0.47) | KAT2BBRD9BPTFALDH1A1HPGD | |
| SCHEMBL12160455 | 0.75 | KAT2B (0.56) | KAT2BBRD9BPTFALDH1A1BRD4 | |
| SCHEMBL4163687 | 0.75 | KAT2B (0.47) | KAT2BBRD9BPTFALDH1A1HPGD | |
| SCHEMBL8549481 | 0.75 | BPTF (0.45) | KAT2BBRD9BPTFALDH1A1HPGD | |
| SCHEMBL14844549 | 0.73 | ALDH1A1 (0.56) | KAT2BBRD9BPTFALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687502-B2 | Substituted quinazoline or pyridopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | MSD K.K. (JP) | 2008-02-07 | — | — | US | disclosed |
| EP-1734040-A1 | SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | GCK, GCKR, PDXK | KAT2B 2994/4885BRD9 1761/4885BPTF 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.